- Home
- GNLX vs ARMP Comparison
GNLX vs ARMP Comparison
Compare GNLX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | ARMP |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 383.7M |
| IPO Year | 2022 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GNLX | ARMP |
|---|---|---|
| Price | $2.49 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $19.80 | $15.00 |
| AVG Volume (30 Days) | ★ 129.7K | 40.8K |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 53.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $0.90 |
| 52 Week High | $8.54 | $13.75 |
Technical Indicators
Market Signals| Indicator | GNLX | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 39.00 |
| Support Level | $2.35 | $5.14 |
| Resistance Level | $2.86 | $8.40 |
| Average True Range (ATR) | 0.14 | 0.92 |
| MACD | -0.02 | -0.48 |
| Stochastic Oscillator | 28.13 | 17.61 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.